Articles tagged with Hiv Treatments
A new study indicates that boosted Invirase results in comparable levels of viral suppression as lopinavir, while also reducing the risk of elevated cholesterol and triglycerides. The treatment also showed fewer gastrointestinal adverse events compared to lopinavir.
Researchers at NC State University are developing mathematical and statistical models to aid in designing new treatment strategies for acutely infected HIV patients. The goal is to predict the best course of treatment based on individual patient variables, which could lead to improved quality of care and personalized treatment.
The Veterans Aging Cohort Study (VACS) has received a five-year award to examine the impact of aging and alcohol use among those with and without chronic HIV infection. The study will investigate the independent effects of these factors, as well as their interaction, on health outcomes.
A new study finds that a community-driven approach to distributing anti-AIDS medications is more equitable and effective than traditional top-down methods. Patients treated through this model showed significant increases in CD4 counts, indicating improved immune system function.
The International AIDS Society guidelines recommend treating HIV patients with an undetectable viral load using a combination of FUZEON and protease inhibitors. This approach is supported by recent clinical trials and has been endorsed by various health organizations, aiming to combat drug resistance and improve treatment outcomes.
A preliminary study suggests that using a single boosted protease inhibitor instead of the standard regimen may be an effective treatment for select patients with HIV infection. The study found that 91% of participants experienced virologic success after 24 weeks of simplified therapy.
The study found that the efavirenz plus two-NRTI regimen was significantly more effective at reducing HIV viral load in the blood. A second approach, lopinavir/ritonavir, also performed well and may be a viable alternative for patients who experience intolerable side effects from NRTIs. The trial included 753 participants and showed su...
The Heineken Workplace Programme, which provides antiretroviral treatment to employees, shows that offering HAART is feasible. By restricting treatment options, companies can manage HIV patients while prioritizing the health of their workforce.
A decade after HAART introduction, HIV/AIDS risk remains low for those starting treatment. However, a significant increase in tuberculosis (TB) cases among HAART patients has been observed since 1998, largely due to increased incidence of TB.
Stopping HIV treatment temporarily can decrease side effects and expenses, however it might cause the disease to progress faster. Researchers discovered that interrupting treatment for certain periods of time was as effective as continuous therapy in controlling the virus.
A Purdue University researcher has developed a molecule that can effectively combat drug-resistant strains of HIV, the virus that causes AIDS. The FDA recently approved the pill-based therapy, known as Darunavir, which is expected to be available to physicians this year.
Global Plan to Stop TB 2006-2015 aims to increase joint TB/HIV programs, benefiting 3 million co-infected with antiretrovirals. Tuberculosis is a leading killer of people living with HIV, and collaboration between communities and governments is crucial to access effective interventions.
A study found that only 15% of adolescent sexual assault survivors completed the full 28-day course of antiviral medications, highlighting difficulties in prescribing therapies to this population. The lack of adherence is attributed to factors such as unclear risk assessment and psychiatric conditions.
The IU School of Medicine has received a $8.9 million grant to expand its HIV/AIDS programs in Kenya. The program, AMPATH, will provide anti-retroviral drug treatments to over 18,000 people by September 2007 and screen more than 25,000 pregnant women annually.
A study of over 500 HIV-positive patients and physicians found significant differences in their perceptions about HIV treatment. Gaps were identified in understanding treatment options, side effects, and patient-physician relationships, highlighting the need for more candid dialogue to improve treatment experiences.
A new study will develop a cohort of 1,000 HIV-infected IDUs with a history of injection drug use to examine treatment access and adherence. The research aims to improve access to life-saving HIV and HCV treatments for marginalized individuals in Vancouver's Downtown Eastside.
A study published in Archives of Dermatology found that injecting polylactic acid can safely and effectively treat facial lipoatrophy in HIV patients, improving skin and fat thickness over 12 months. The treatment showed significant results, with increased dermal thickness persisting beyond the initial six injections.
Researchers found that low-income settings had higher mortality rates due to accompanying illnesses like tuberculosis, but free treatment provision was strongly associated with lower mortality. HAART should be started earlier and eligibility determined before comorbidities develop.
A recent study found that 76% of treatment-experienced patients would consider using a self-injectable HIV therapy if recommended by their physician. Despite this, only one quarter of eligible patients have discussed the option with their doctors, highlighting a significant barrier to adoption.
The introduction of generic ART led to a significant decline in HIV-related deaths in India between 1997 and 2003. Accessible drugs have also reduced the incidence of opportunistic infections such as tuberculosis among immunocompromised patients.
A UN report estimates over 79,500 people with HIV/AIDS were evicted, disrupting antiretroviral treatment and home-based care. WHO-AFRO should take the lead in providing humanitarian assistance to address the escalating health crisis and potential public health disaster.
The prevalence of unprotected anal sex with casual partners increased by 10% between 1996 and 2002, with rates higher among those who were less optimistic about HIV treatment. Renewed national efforts are needed to counteract 'prevention fatigue' and promote effective HIV prevention strategies.
A study of over 3,200 HIV patients found that HAART substantially reduces the rate of AIDS progression by 86% compared to no treatment. The effectiveness of HAART increases with time since initiation, but its benefits are reduced for patients who contracted HIV through intravenous drug use.
Studies show that FUZEON combined with tipranavir achieves a ten-fold reduction in viral load and double the increase in immune cell count. The 'FUZEON effect' has been seen across multiple studies, nearly doubling patients reaching undetectable viral loads.
A new study found that patient-delivered partner treatment reduces STD recurrence and transmission. The method involves giving patients antibiotics to offer to their partners, resulting in higher referral rates and reduced unprotected sex.
A new, low-cost device can accurately count CD4 cells in HIV-infected individuals, enabling early treatment decisions and improving patient outcomes. The portable handheld model is designed for healthcare workers in remote areas, addressing a critical need in low-income countries.
Global HIV/AIDS cases are increasing worldwide, with Africa being only one of the regions affected. The Lancet study highlights the need for international cooperation and resource allocation to address this growing epidemic.
Women now account for nearly half of the 40 million people worldwide infected with HIV, a significant shift from the early days of the pandemic. The increased number of female cases is attributed to various factors, including heterosexual transmission and cultural influences.
Research shows that early institution of ART therapy can delay and decrease HIV progression in perinatal HIV infection. Untreated children are more likely to progress, but very early mono/dual ART initiation by age 2 months offers improved survival rates.
A recent study by Emory University Health Sciences Center found that patients newly diagnosed with HIV are more likely to enter outpatient care with case management. The study showed that 78% of patients with case management visited an HIV clinician at least once within 6 months, compared to 60% in the standard-of-care group.
The study examines lessons learned from Africa's first public ARV treatment clinic in Botswana, highlighting the need for consistent care and ongoing training for staff. The clinic has successfully treated thousands of patients, but challenges persist in staffing and infrastructure.
A modeling study published in PLoS Medicine suggests that integrating HIV prevention and treatment efforts could prevent up to 10 million AIDS deaths in Africa by 2020, with a predicted 74% reduction in new infections and 50% decrease in annual mortality.
Researchers at City of Hope Cancer Center have successfully treated 17 out of 20 HIV-positive patients with refractory lymphoma using high-dose chemotherapy and autologous stem cell rescue. The study shows promising results with an 85% survival rate, paving the way for further investigation into this potential cure.
The US government has awarded grants to support HIV/AIDS research and treatment in resource-limited countries, including Cambodia, Peru, Thailand, and Russia. The grants aim to develop clinical research centers and evaluate new treatments for co-infections with tuberculosis.
Researchers found that custom-designed facial implants provided excellent aesthetic postoperative outcomes for 22 patients with facial wasting syndrome. The use of high-resolution CT scans enabled precise modeling and sizing of implants, leading to stable and long-lasting results.
A study published in PLOS Medicine found that supervised treatment interruptions, which aim to boost natural immunity by briefly exposing patients to low levels of the virus, are ineffective in controlling HIV-1 viremia. Researchers were able to achieve transient control of the virus in some patients, but it was not sustained over time.
The St. Petersburg/New Haven Partnership aims to develop a community-wide HIV/AIDS care program in Russia, with training and exchanges between American and Russian health professionals. Led by Yale's Krystn Wagner and Robert Heimer, the partnership seeks to improve HIV/AIDS care and treatment in Russia.
The study found that HAART reduced mortality in HIV-infected injection drug users with high CD4 cell counts, similar to those without HIV. Initiating or switching to HAART at higher CD4 counts than current recommendations may improve outcomes for asymptomatic patients.
A new treatment combination of peginterferon and ribavirin has been shown to significantly improve viral control in patients with both HIV and hepatitis C. The study found that 40% of patients treated with peginterferon achieved HCV clearance, compared to 12% on the standard interferon treatment.
Researchers have identified a more effective treatment for people with both HIV and hepatitis C. The new therapy, peg-interferon with ribavirin, showed a sustained response rate of 27% compared to 12% in those who received standard interferon treatment.
FUZEON shows significant benefits in health improvements and reduced side effects for HIV patients, yet many are missing out due to fear of injection. Physicians and nurses play a pivotal role in educating patients on optimal use of FUZEON.
A clinical trial in Cameroon shows a generic fixed-dose antiretroviral tritherapy to be as effective as conventional therapies, with good patient compliance and high quality of the treatment. The treatment, which costs $20 per month, is well tolerated and provides a cost-effective solution for HIV treatment in developing countries.
Researchers found that a weekly cycle of once-daily anti-HIV drugs can effectively treat HIV infection while reducing medication costs. The study involved eight patients who received a treatment regimen of 7 days on, followed by 7 days off, and maintained undetectable levels of HIV in their bloodstream for up to 84 weeks.
New guidelines suggest FUZEON is an important treatment for HIV drug resistance, offering clear advice on timing of initiation and patient support. The guidelines aim to enable more pre-treated patients to benefit from FUZEON therapy.
A study found that HIV-positive women are more likely to engage in unprotected sex due to a lack of empowerment or low self-esteem. Ongoing risk-reduction counseling and substance abuse treatment are crucial to curb high-risk behavior, experts say.
The Lancet editorial proposes a serostatus-based approach for universal voluntary knowledge of HIV status, simplified clinical testing, and prevention of discrimination. Two viewpoints discuss the necessity of testing before prophylaxis with single-dose nevirapine in preventing mother-to-child transmission.
Researchers found that total lymphocyte count and albumin independently predicted the risk of death in HIV-1-infected children. Using these low-cost measures could establish when to initiate antiretroviral therapy in settings where CD4 and RNA assays are not available.
The new program combines counseling and education efforts with medical therapy to reduce HIV levels in patients. The initiative aims to assess the impact of integrating prevention services into primary care on HIV risk behaviors and outcomes.
A new dried blood-spot test has shown promising results for monitoring HIV treatment in less-developed countries. The test, which uses a commercial enzyme immunoassay, compares well with standard flow cytometry and could make CD4+ lymphocyte count measurements more accessible to rural populations.
A study suggests that new HIV treatments can lead to a decrease in people's concerns about the disease, resulting in increased transmission rates. Researchers believe that health professionals should address this issue by revamping prevention messages and programs.
Researchers found that structured treatment interruption in people with multidrug-resistant HIV led to more HIV-related complications and poorer immune response. The study suggests that continuing therapy guided by HIV drug resistance testing is a better approach for this group of HIV-infected individuals.
NC State statisticians Drs. Anastasios Tsiatis, Marie Davidian and Marc Genton have won a $1.125 million NIH MERIT Award for their work on statistical methodology in designing complex HIV clinical trials. Their research aims to develop sophisticated designs that can handle the variability of patients' responses to treatment.
A new study found that Gleevec significantly reduced Kaposi's sarcoma lesions in five HIV-positive patients, with one patient experiencing a 90% regression. The therapy targets cancer cells and eliminates debilitating side effects associated with chemotherapy.
A study of 487 cocaine-dependent patients found that treatment combining group drug counseling with individual therapy reduced HIV risk. The combination treatment showed the best improvements in reducing cocaine use, resulting in a 40% decrease in HIV risk.
Designing molecules to block HIV receptors could lead to more effective and safer treatments. The approach has the potential to be orders of magnitude more effective than existing treatments, with fewer side effects.
Methadone treatment is being expanded to office-based practices for patients with addiction, aiming to make it more accessible. Hair analysis has been found to be a significant advance in assessing exposure to antiretroviral therapies and monitoring patient response to indinavir, an anti-HIV drug.
Research by James P. Smith and Dana P. Goldman found that education level is a significant factor in adherence to treatment regimens, particularly for complex diseases like HIV and diabetes. The study suggests that education can help improve health outcomes by promoting better adherence to treatment plans.
Researchers found that HIV-infected patients with viral suppression interrupted treatment for an average of nine months without experiencing infections or illnesses. Patients with lower virus levels and stronger immune systems responded favorably to the interruption.
A Franco-Senegalese research team has demonstrated the efficacy of antiretroviral therapy in Africa, contrary to previous doubts. The 18-month pilot scheme showed strong adherence and high patient respect for prescriptions, with improved treatment outcomes.
A pilot study in Uganda found that patients with advanced HIV disease can survive and thrive with antiretroviral therapy. The program implemented an effective system for medical care and drug distribution, resulting in improved adherence to treatment and better virologic responses.